Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Craig S Glazer"'
Autor:
Kim C Styrvoky, Kiran Batra, Mark Robertshaw, Margaret Kypreos, An Lu, Craig S Glazer, Traci N Adams
Publikováno v:
PLoS ONE, Vol 18, Iss 5, p e0285634 (2023)
BackgroundBronchoalveolar lavage and transbronchial biopsy can increase diagnostic confidence in the diagnosis of hypersensitivity pneumonitis (HP). Improving the yield of bronchoscopy may help to improve diagnostic confidence while decreasing the ri
Externí odkaz:
https://doaj.org/article/bc103bf3fd084c9bb91a5ec3df2df6e8
Publikováno v:
PLoS ONE, Vol 17, Iss 9, p e0273544 (2022)
BackgroundIdentification of inciting antigen can affect diagnostic confidence, quality of life, and prognosis in patients with HP. It is unknown whether the number and type of antigen affect results of diagnostic testing or prognosis, whether antigen
Externí odkaz:
https://doaj.org/article/005b84e77ebe4fc792d532de7149328a
Autor:
Alberto Diaz de Leon, Jennifer T Cronkhite, Anna-Luise A Katzenstein, J David Godwin, Ganesh Raghu, Craig S Glazer, Randall L Rosenblatt, Carlos E Girod, Edward R Garrity, Chao Xing, Christine Kim Garcia
Publikováno v:
PLoS ONE, Vol 5, Iss 5, p e10680 (2010)
Telomerase is an enzyme that catalyzes the addition of nucleotides on the ends of chromosomes. Rare loss of function mutations in the gene that encodes the protein component of telomerase (TERT) have been described in patients with idiopathic pulmona
Externí odkaz:
https://doaj.org/article/fd1501fde8a94ec7b8fafef226b711f5
Addition of antifibrotic therapy to immunosuppression in hypersensitivity pneumonitis: A case series
Publikováno v:
Respiratory Medicine Case Reports, Vol 34, Iss , Pp 101562- (2021)
Hypersensitivity pneumonitis has historically been treated with immunosuppression, but recently nintedanib was approved for the treatment of progressive fibrotic HP. One limitation of INBUILD is that the only immunosuppression (IS) permitted at the t
Externí odkaz:
https://doaj.org/article/6db563928dc3474b9d738cf2abd5d1d5
Autor:
Joshua J. Mooney, Daniel A. Culver, Sachin Chaudhary, Murali Ramaswamy, Gregory P. Cosgrove, Alpa G. Desai, Sonye K. Danoff, Amy Case, Stephen Weight, Rodeo Abrencillo, Joseph D. Zibrak, Srihari Veeraraghavan, Barry S. Shea, Nitin Y. Bhatt, Maryl Kreider, Doug Moore, Mary Beth Scholand, Shelley L. Schmidt, Thomas H. Schaumberg, Christopher S. King, Borna Mehrad, Justin M. Oldham, Bridget A. Graney, Adrian Shifren, Christophe He, Nathan Sandbo, Nishant Gupta, Michael Marll, Daniel F. Dilling, Tracy Luckhardt, Mridu Gulati, Tristan J. Huie, Craig S. Glazer, Nevins W. Todd, Peter Lacamera, Hyun Koo Kim, Mohamed Saad, Pauline Bianchi, James R. McCormick, Mark Hamblin, Yolanda N. Mageto, Robert Matthew Kottman, Teng Moua, Anna J. Podolanczuk, Scott Matson, Divya Patel, David Roe, Mary E. Strek, Lisa Lancaster, Krishna Thavarajah, Paul J. Wolters, Joyce S. Lee, Sydney B. Montesi, Rafael L. Perez, Rebecca Bascom, Nabeel Hamzeh, Tessy K. Paul, Anoop M. Nambiar, Prema Menon
Publikováno v:
Chest. 159:1517-1530
Background Management of patients with interstitial lung disease (ILD) requires subspecialized, comprehensive, multidisciplinary care. The Pulmonary Fibrosis Foundation established the Care Center Network (CCN) in 2013 with identified criteria to bec
Autor:
Vikram Anand, Samantha A. Moore, Craig S. Glazer, Traci N. Adams, Kiran Batra, Yasmeen M. Butt, Jose R. Torrealba, Elena K. Joerns, Leann Silhan, Chad A. Newton
Publikováno v:
Lung
PURPOSE: Bronchoalveolar lavage and transbronchial biopsy can be a useful tool in the evaluation of interstitial lung disease (ILD), but patient selection for this procedure remains poorly defined. Determining clinical characteristics that help with
Autor:
Jose R. Torrealba, Bonnie L. Bermas, Traci N. Adams, Una E. Makris, Lesley Davila, Craig S. Glazer, Joan S. Reisch, Chad A. Newton, Kiran Batra, Elena K. Joerns, David R. Karp
Publikováno v:
Journal of clinical rheumatology : practical reports on rheumaticmusculoskeletal diseases. 28(2)
We have limited knowledge regarding characteristics of patients with interstitial pneumonia with autoimmune features (IPAF) that are associated with response to immunosuppression. In this study, we used published IPAF criteria to characterize feature
Addition of antifibrotic therapy to immunosuppression in hypersensitivity pneumonitis: A case series
Publikováno v:
Respiratory Medicine Case Reports, Vol 34, Iss, Pp 101562-(2021)
Respiratory Medicine Case Reports
Respiratory Medicine Case Reports
Hypersensitivity pneumonitis has historically been treated with immunosuppression, but recently nintedanib was approved for the treatment of progressive fibrotic HP. One limitation of INBUILD is that the only immunosuppression (IS) permitted at the t
Autor:
Stefania Cerri, Maria Otaola, Vincent Cottin, Toby M. Maher, Craig S. Glazer, Diego Castillo Villegas, Carl Coeck, Nazia Chaudhuri, Manuel Quaresma, Heiko Müller, Michael Kreuter
Publikováno v:
ILD / DPLD of known origin.
Background: In the INBUILD trial, nintedanib slowed FVC decline in patients with non-IPF progressive fibrosing ILDs. Aim: Assess the influence of disease-modifying antirheumatic drugs (DMARDs) and/or glucocorticoids at baseline on the effect of ninte
Autor:
Muhanned Abu-Hijleh, Chad A. Newton, Tyonn Barbera, Jose R. Torrealba, Kiran Batra, Craig S. Glazer, Traci N. Adams
Publikováno v:
Lung. 196:617-622
INTRODUCTION: Making the diagnosis of HP is challenging due to a lack of consensus criteria and variability of both pathologic and radiographic findings. The purpose of this retrospective study was to determine the diagnostic utility of the combinati